Statement of Advice:

adalimumab (Humira®) Pre-filled Pen, Pre-filled Syringe and Vial
(No: 1173/16)
AbbVie Limited

10 June 2016

ADVICE: in the absence of a submission from the holder of the marketing authorisation

adalimumab (Humira®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08).

SMC has previously accepted adalimumab for restricted use for the treatment of chronic plaque psoriasis in adult patients who failed to respond to or have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA. It is restricted to patients with severe disease as defined by a total Psoriasis Area Severity Index score of ≥10 and a Dermatology Life Quality Index of >10. (SMC 468/08). This advice remains valid.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman,
Scottish Medicines Consortium

Published 11 July 2016